Corient Private Wealth
PRTK

Corient Private Wealth’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Corient Private Wealth’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,550
Closed -$34.4K – 2258
2023
Q2 		$34.4K Hold
15,550
– – ﹤0.01% 2037
2023
Q1 		$39.5K Hold
15,550
– – ﹤0.01% 1955
2022
Q4 		$29.1K Buy
+15,550
New +$38.8K ﹤0.01% 1659

Corient Private Wealth's PRTK Position: Q3 2023 in Review

Corient Private Wealth sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 15,550 shares — an estimated $34.4K sold.

Corient Private Wealth first reported a position in PRTK in Q4 2022 and held it in 3 quarters. The position peaked at $39.5K in Q1 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

  • Corient Private Wealth reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Corient Private Wealth sold 15,550 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $34.4K.
  • Corient Private Wealth first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2022 and held it in 3 quarters.
  • Corient Private Wealth's Paratek Pharmaceuticals, Inc. position peaked at $39.5K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Corient Private Wealth's 13F filing for Q3 2023, filed 3 Nov 2023.